Montis Biosciences
Description
Montis Biosciences is developing next generation therapeutics to treat neurodegenerative and autoimmune diseases, and selected cancer indications. Leveraging its unique patient-centric discovery platform, Montis has developed potent antibodies against two novel targets.
The first program (MB01) selectively targets C1q, first mediator of the classical complement, bringing a paradigm shift in targeting the complement in neurodegenerative and auto-immune diseases.
The second program (MB02) focuses on targeting CD93 , a novel perivascular target, in selected oncology indications. A lead candidate has been selected and aims to bring patient benefit in lung squamous cancer and other high unmet need indications.
Montis is backed by a strong investor syndicate: Droia Ventures, Pfizer Ventures, Polaris Innovation Fund and ALSA Ventures and is raising a Series A financing round.
elected s of high unmet need
